Figure 2(c) illustrates that JAK2 inhibition blocks the effect of FSGS sera on Palb activity of sera from FSGS patients (Figure 2 depicts data previously published [9, 10]). This evidence concerns the gene TTR and focal segmental glomerulosclerosis.